IUdR/BUdR Cell Cycle Labelling

M.D. Anderson Cancer Center

Status: Completed

Conditions: Hematologic Malignancies

Treatments: Drug: Chemotherapy for hematologic malignancy

Study type: Interventional

Funder types: Other

Identifiers

NCT00042250

DM91-102

Details and patient eligibility

About

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Full description

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Histologic proof of one of:

• AML, ALL, or AUL
• MDS or CMML
• CML
• OR undergoing bone marrow transplantation.

Participants should be:

• off therapy for at least two weeks
• At least 18 years old or older
• Using adequate contraception if of child-bearing capability.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)